Imagion Biosystems has initiated manufacturing of its MagSense imaging agent for its phase II clinical study on HER2+ breast cancer. ... Read More The post Imagion to start production of MagSense ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Tuesday unveiled its strategic outlook for the year and said that 2025 will be decisive for the company, with several major initiatives to accelerate the clinical development of BIO101 ...

(4 hours per week) Throughout the pre-clerkship phase, the Physicians, Patients and Populations (PPP) courses develop physician-patient knowledge and competencies related to clinical skills. PPP ...